MycoLogics, Inc. Focuses On The Isolation Of New Classes Of Compounds For Treatment Of Human Fungal Disease
10/19/2005 5:10:11 PM
MycoLogics, Inc., an innovative biotechnology company specializing in the development of therapeutic and prophylactic vaccines against human fungal and parasitic pathogens, today announced award of a Phase I SBIR grant by the Department of Health and Human Services to isolate a new class of compounds to treat human fungal disease by disrupting beta(1,6)-glucan synthesis. The beta(1,6)-glucan polymer is an essential component for fungal growth, it is found in fungi not in humans and, therefore is an excellent target for the development of antifungal drugs.
comments powered by